GAITHERSBURG, Md., Sept. 12 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. will present data on their novel and proprietary cancer biomarker during the Molecular Diagnostics in Cancer Therapeutic Development meeting, sponsored by the American Association for Cancer Research, starting today in Chicago. The Company's scientists will give a presentation on the utility of gene expression of Human aspartyl (asparaginyl) Beta-hydroxylase (HAAH) as a biomarker to diagnose and monitor disease status in patients with Acute Myelogenous Leukemia (AML), along with a poster describing data supporting serum HAAH as a biomarker for prostate cancer. In addition, Company scientists will present a poster on the manufacture of anti-HAAH antibodies as potential human therapeutics.
